Evidence map›Paper›PMID 33378680›Full record

ArticleCell reports2020

Pressure-Driven Mitochondrial Transfer Pipeline Generates Mammalian Cells of Desired Genetic Combinations and Fates.

Alexander N Patananan, Alexander J Sercel, Ting-Hsiang Wu, Fasih M Ahsan, Alejandro Torres, Stephanie A L Kennedy, Amy Vandiver, Amanda J Collier, Artin Mehrabi, Jon Van Lew and 17 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Therapeutic Potential of Mitochondrial Transplantation with Focus on DBD.International journal of molecular sciences · 2026
    Review
  7. Review
  8. Mitochondrial transplant activates CaStem cell research & therapy · 2026
    Article
  9. Review
  10. Review
  11. Nanomaterial-induced mitochondrial biogenesis enhances intercellular mitochondrial transfer efficiency.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 3 institutions in 1 country.

Alexander N PatanananDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Alexander J SercelMolecular Biology Interdepartmental Program, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Ting-Hsiang WuNanoCav LLC, Culver City, CA 90232, USA.
Fasih M AhsanDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Alejandro TorresDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Stephanie A L KennedyDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Amy VandiverDivision of Dermatology, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Amanda J CollierDepartment of Biological Chemistry, University of California, Los Angeles, Los Angeles, CA 90095, USA; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Artin MehrabiNanoCav LLC, Culver City, CA 90232, USA.
Jon Van LewNanoCav LLC, Culver City, CA 90232, USA.
Lise ZakinNantWorks, LLC, Culver City, CA 90232, USA.
Noe RodriguezNantWorks, LLC, Culver City, CA 90232, USA.
Marcos SixtoNantWorks, LLC, Culver City, CA 90232, USA.
Wael TadrosNantWorks, LLC, Culver City, CA 90232, USA.
Adam LazarNantWorks, LLC, Culver City, CA 90232, USA.
Peter A SielingNantWorks, LLC, Culver City, CA 90232, USA.
Thang L NguyenDepartment of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Emma R DawsonDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Daniel BraasUCLA Metabolomics Center, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Justin GolovatoNantOmics, LLC, Culver City, CA 90232, USA.
Luis CisnerosNantOmics, LLC, Culver City, CA 90232, USA.
Charles VaskeNantOmics, LLC, Culver City, CA 90232, USA.
Kathrin PlathDepartment of Biological Chemistry, University of California, Los Angeles, Los Angeles, CA 90095, USA; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Shahrooz RabizadehNanoCav LLC, Culver City, CA 90232, USA; NantWorks, LLC, Culver City, CA 90232, USA.
Kayvan R NiaziNanoCav LLC, Culver City, CA 90232, USA; NantWorks, LLC, Culver City, CA 90232, USA.
Pei-Yu ChiouDepartment of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Mechanical and Aerospace Engineering, University of California, Los Angeles, Los Angeles, CA 90095, USA; California NanoSystems Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Michael A TeitellDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095, USA; California NanoSystems Institute, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Pediatrics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address: mteitell@mednet.ucla.edu.
University of California, Los Angeles · USNantWorks (United States) · USCalifornia NanoSystems Institute · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA NIGMS T32 Program AssessmentT32GM007185 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TORRES, JORGE · 1985 to 2020
$21.7M
Roles of sumoylation and alternative polyadenylation in cellular reprogrammingP01GM099134 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PLATH, KATHRIN · 2011 to 2021
$20.3M
UCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3M
MARC U*STAR Program at the University of California, Los AngelesT34GM008563 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MCEVOY, MEGAN M, POE, GINA R · 1996 to 2023
$9.7M
RNA trafficking in mitochondriaR01GM073981 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Carla M Koehler, MICHAEL A TEITELL · 2006 to 2026
$5.1M
(PQD5) Mass Profiling Melanoma Responses to Improve Therapy Choices and PrognosisR01CA185189 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REED, JASON C, TEITELL, MICHAEL A · 2014 to 2017
$1.9M
Reverse Mitochondrial Genetics Enabled by BlastR01GM114188 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHIOU, PEI-YU, TEITELL, MICHAEL A · 2015 to 2018
$1.9M
SPOTs: Optical Technologies for Instantly Quantifying Multicellular Response ProfilesR01GM127985 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHIOU, PEI-YU, TEITELL, MICHAEL A · 2020 to 2023
$1.7M
Enhancing the Efficiency of Non-REM Sleep Temporal Dynamics to Improve Insight LearningR21MH119020 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI POE, GINA R · 2019 to 2020
$442k
Microfluidics-Integrated Photothermal Nanoblade for High-Throughput Large Cargo DR21EB014456 · NIBIB · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHIOU, PEI-YU, TEITELL, MICHAEL A · 2012 to 2013
$387k
(PQ5) Mitochondrial Transfer in Tumor Heterogeneity and Acquired Resistence to TherapyR21CA227480 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TEITELL, MICHAEL A · 2019 to 2020
$373k
NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA185189NCI NIH HHS R21 CA227480NCI NIH HHS T32 CA009120NIBIB NIH HHS R21 EB014456NIGMS NIH HHS P01 GM099134NIGMS NIH HHS R01 GM073981NIGMS NIH HHS R01 GM114188NIGMS NIH HHS R01 GM127985NIGMS NIH HHS T32 GM007185NIGMS NIH HHS T34 GM008563NIMH NIH HHS R21 MH119020
6 · The paper itself

Abstract

Generating mammalian cells with desired mitochondrial DNA (mtDNA) sequences is enabling for studies of mitochondria, disease modeling, and potential regenerative therapies. MitoPunch, a high-throughput mitochondrial transfer device, produces cells with specific mtDNA-nuclear DNA (nDNA) combinations by transferring isolated mitochondria from mouse or human cells into primary or immortal mtDNA-deficient (ρ0) cells. Stable isolated mitochondrial recipient (SIMR) cells isolated in restrictive media permanently retain donor mtDNA and reacquire respiration. However, SIMR fibroblasts maintain a ρ0-like cell metabolome and transcriptome despite growth in restrictive media. We reprogrammed non-immortal SIMR fibroblasts into induced pluripotent stem cells (iPSCs) with subsequent differentiation into diverse functional cell types, including mesenchymal stem cells (MSCs), adipocytes, osteoblasts, and chondrocytes. Remarkably, after reprogramming and differentiation, SIMR fibroblasts molecularly and phenotypically resemble unmanipulated control fibroblasts carried through the same protocol. Thus, our MitoPunch "pipeline" enables the production of SIMR cells with unique mtDNA-nDNA combinations for additional studies and applications in multiple cell types.

Indexed as

Cellular ReprogrammingGene Transfer TechniquesAnimalsCell DifferentiationCell LineDNA, MitochondrialFibroblastsHEK293 CellsHigh-Throughput Screening AssaysHumansInduced Pluripotent Stem CellsMetabolomeMiceMice, Inbred C57BLMitochondriaTranscriptomeDNA, Mitochondrialcell engineeringdifferentiation, MitoPunch, mitochondrial transplantation, mitochondrial replacement, mitonuclear communication, isolated mitochondriamitochondrial transfermtDNAreprogramming

Identifiers

PMID33378680
PMCPMC7927156
OpenAlexW3117773859

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.